|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
JULY 10, 2006
Pounce On Acusphere  Acusphere (ACUS
) (ACUS) took a dive on June 6, when it announced mixed results from trials of a new product. The stock, which stood at 5.64 on June 5, fell to 2.99 on June 28. Some analysts spy a chance to buy. The product in Phase 3 clinical trials is AI-700, an ultrasound contrast agent aimed at better diagnosis of heart disease. It lets doctors look at blood flow within the heart muscle, a use for which no product has yet been approved. AI-700 passed only two of three tests in the Phase 3 trials. "The stock is oversold," says David Moskowitz of Friedman, Billings, Ramsey, who rates it "outperform" with a 12-month target of 12. Investors ignored the "highly positive accuracy and specificity results in the [first part of the] trial," says Moskowitz. And the market is acting as if AI-700 won't get Food & Drug Administration approval, but that isn't so, says Deborah Knobleman of investment firm Piper Jaffray (PJC
) who tags it a "buy." She expects the second part of the trials to show more favorable results. So does Alexandra H. Utterman, senior analyst at investment bank William D. Witter, which owns shares. The stock is "oversold and trading way below its intrinsic value," she says.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version